Redox Imbalance and Viral Infections in Neurodegenerative Diseases

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Limongi, Dolores ^a   Baldelli, Sara ^a  

^a Faculty of Architecture and Industrial Design   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOGENIC VIRUSES;

ALZHEIMER'S DISEASE; AMYOTROPHIC LATERAL SCLEROSES (ALS); HERPES SIMPLEX VIRUS; MOLECULAR MECHANISM; NEURODEGENERATIVE DISORDERS; PARKINSON'S DISEASE; PHYSIOLOGICAL FUNCTIONS; REACTIVE OXYGEN SPECIES;

NEURODEGENERATIVE DISEASES;

REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN CELL; DEGENERATIVE DISEASE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; INFECTION RISK; INFLAMMATION; INFLUENZA; NERVE DEGENERATION; NONHUMAN; OXIDATION REDUCTION STATE; PARKINSON DISEASE; PATHOGENESIS; RETROVIRUS INFECTION; REVIEW; SECOND MESSENGER; VIRUS INFECTION; ANIMAL; COMPLICATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; VIROLOGY;

ANIMALS; HUMANS; INFLAMMATION; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; VIRUS DISEASES;

EID: 84971434968     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/6547248     Document Type: Review

References (180)

1. B. Halliwell, "Oxidative stress and neurodegeneration: where are we now?" Journal of Neurochemistry, vol. 97, no. 6, pp. 1634-1658, 2006.
2. P. M. Carvey, A. Punati, and M. B. Newman, "Progressive dopamine neuron loss in Parkinson's disease: The multiple hit hypothesis, " Cell Transplantation, vol. 15, no. 3, pp. 239-250, 2006.
3. N. Shahani, S. Subramaniam, T. Wolf, C. Tackenberg, and R. Brandt, "Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices, " The Journal of Neuroscience, vol. 26, no. 22, pp. 6103-6114, 2006.
4. K. A. Jellinger, "Basic mechanisms of neurodegeneration: A critical update, " Journal of Cellular andMolecularMedicine, vol. 14, no. 3, pp. 457-487, 2010.
5. S. Gandhi and A. Y. Abramov, "Mechanism of oxidative stress in neurodegeneration, " OxidativeMedicine and Cellular Longevity, vol. 2012, Article ID428010, 11 pages, 2012.
6. Q. Wang, L. Qian, S.-H. Chen et al., "Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models, " Brain, vol. 138, no. 5, pp. 1247-1262, 2015.
7. J. K. Andersen, K. J. A. Davies, and H. J. Forman, "Reactive oxygen and nitrogen species in neurodegeneration, " Free Radical Biology and Medicine, vol. 62, pp. 1-3, 2013.
8. J. E. Yuste, E. Tarragon, C. M. Campuzano, and F. Ros-Bernal, "Implications of glial nitric oxide in neurodegenerative diseases, " Frontiers in Cellular Neuroscience, vol. 9, article 322, 2015.
9. S. Aras, G. Tanriover, M. Aslan, P. Yargicoglu, and A. Agar, "The role of nitric oxide on visual-evoked potentials inMPTPinduced Parkinsonism in mice, " Neurochemistry International, vol. 72, no. 1, pp. 48-57, 2014.
10. A. B. Knott and E. Bossy-Wetzel, "Nitric oxide in health and disease of the nervous system, " Antioxidants and Redox Signaling, vol. 11, no. 3, pp. 541-554, 2009.
11. K. Aquilano, S. Baldelli, G. Rotilio, and M. R. Ciriolo, "Role of nitric oxide synthases in Parkinson's disease: A review on the antioxidant and anti-inflammatory activity of polyphenols, " Neurochemical Research, vol. 33, no. 12, pp. 2416-2426, 2008.
12. E. J. Nelson, J. Connolly, and P. McArthur, "Nitric oxide and S-nitrosylation: excitotoxic and cell signalingmechanism, " Biology of the Cell, vol. 95, no. 1, pp. 3-8, 2003.
13. J. D. Marks, C. Boriboun, and J. Wang, "Mitochondrial nitric oxide mediates decreased vulnerability of hippocampal neurons fromimmature animals toNMDA, "TheJournal ofNeuroscience, vol. 25, no. 28, pp. 6561-6575, 2005.
14. R. von Bernhardi and J. Eugenín, "Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms, " Antioxidants and Redox Signaling, vol. 16, no. 9, pp. 974-1031, 2012.
15. V. Chiurchiù and M. Maccarrone, "Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities, "Antioxidants and Redox Signaling, vol. 15, no. 9, pp. 2605-2641, 2011.
16. A. Klugman, D. P. Naughton, M. Isaac, I. Shah, A. Petroczi, and N. Tabet, "Antioxidant enzymatic activities in alzheimer's disease: The relationship to acetylcholinesterase inhibitors, " Journal of Alzheimer's Disease, vol. 30, no. 3, pp. 467-474, 2012.
17. M. Smeyne and R. J. Smeynen, "Glutathione metabolism and Parkinson's disease, " Free Radical Biology and Medicine, vol. 62, pp. 13-25, 2013.
18. E. Sofic, K. W. Lange, K. Jellinger, and P. Riederer, "Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease, " Neuroscience Letters, vol. 142, no. 2, pp. 128-130, 1992.
19. G. N. Babu, A. Kumar, R. Chandra et al., "Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease, " Neurochemistry International, vol. 52, no. 6, pp. 1284-1289, 2008.
20. H. Yamazaki, K. Tanji, K. Wakabayashi, S. Matsuura, and K. Itoh, "Role of the Keap1/Nrf2 pathway in neurodegenerative diseases, " Pathology International, vol. 65, no. 5, pp. 210-219, 2015.
21. H. K. Bryan, A. Olayanju, C. E. Goldring, and B. K. Park, "The Nrf2 cell defence pathway: Keap1-dependent and-independent mechanisms of regulation, " Biochemical Pharmacology, vol. 85, no. 6, pp. 705-717, 2013.
22. C. P. Ramsey, C. A. Glass, M. B. Montgomery et al., "Expression of Nrf2 in neurodegenerative diseases, " Journal of Neuropathology and Experimental Neurology, vol. 66, no. 1, pp. 75-85, 2007.
23. A. Sarlette, K. Krampfl, C. Grothe, N. V. Neuhoff, R. Dengler, and S. Petri, "Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis, " Journal ofNeuropathology and Experimental Neurology, vol. 67, no. 11, pp. 1055-1062, 2008.
24. M. P. Mattson, "Infectious agents and age-related neurodegenerative disorders, " Ageing Research Reviews, vol. 3, no. 1, pp. 105-120, 2004.
25. K. Matsuda, C. H. Park, Y. Sunden et al., "The vagus nerve is one route of transneural invasion for intranasally inoculated influenza A virus in mice, " Veterinary Pathology, vol. 41, no. 2, pp. 101-107, 2004.
26. S. Amor, F. Puentes, D. Baker, and P. Van Der Valk, "Inflammation in neurodegenerative diseases, " Immunology, vol. 129, no. 2, pp. 154-169, 2010.
27. S. J. Shipley, E. T. Parkin, R. F. Itzhaki, and C. B. Dobson, "Herpes simplex virus interfereswith amyloid precursor protein processing, " BMC Microbiology, vol. 5, article 48, 2005.
28. M. A. Wozniak, R. F. Itzhaki, S. J. Shipley, and C. B. Dobson, "Herpes simplex virus infection causes cellular amyloid accumulation and secretase upregulation, " Neuroscience Letters, vol. 429, no. 2-3, pp. 95-100, 2007.
29. A. Rahal, A. Kumar, V. Singh et al., "Oxidative stress, prooxidants, and antioxidants: The interplay, " BioMed Research International, vol. 2014, Article ID 761264, 19 pages, 2014.
30. M. P. Murphy, "How mitochondria produce reactive oxygen species, " Biochemical Journal, vol. 417, no. 1, pp. 1-13, 2009.
31. M. Marí, A. Morales, A. Colell, C. García-Ruiz, N. Kaplowitz, and J. C. Fernández-Checa, "Mitochondrial glutathione: features, regulation and role in disease, " Biochimica et Biophysica Acta-General Subjects, vol. 1830, no. 5, pp. 3317-3328, 2013.
32. R. P. Brandes, N. Weissmann, and K. Schröder, "Nox family NADPH oxidases: molecular mechanisms of activation, " Free Radical Biology and Medicine, vol. 76, pp. 208-226, 2014.
33. S. J. Cooney, S. L. Bermudez-Sabogal, and K. R. Byrnes, "Cellular and temporal expression of NADPH oxidase (NOX) isotypes after brain injury, " Journal of Neuroinflammation, vol. 10, article 155, 2013.
34. D. Amatore, R. Sgarbanti, K. Aquilano et al., "Influenza virus replication in lung epithelial cells depends on redox-sensitive pathways activated by NOX4-derived ROS, " CellularMicrobiology, vol. 17, no. 1, pp. 131-145, 2015.
35. L. Qin, Y. Liu, J.-S. Hong, and F. T. Crews, "NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration, " Glia, vol. 61, no. 6, pp. 855-868, 2013.
36. D. A. Butterfield, T. Reed, S. F. Newman, and R. Sultana, "Roles of amyloid peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment, " Free Radical Biology and Medicine, vol. 43, no. 5, pp. 658-677, 2007.
37. M. P. Murphy and H. Levine III, "Alzheimer's disease and the amyloid-peptide, " Journal of Alzheimer's Disease, vol. 19, no. 1, pp. 311-323, 2010.
38. L. I. Binder, A. L. Guillozet-Bongaarts, F. Garcia-Sierra, and R. W. Berry, "Tau, tangles, and Alzheimer's disease, " Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1739, no. 2-3, pp. 216-223, 2005.
39. K. Ando, Q. Laborde, A. Lazar et al., "Inside Alzheimer brain with CLARITY: senile plaques, neurofibrillary tangles and axons in 3-D, " Acta Neuropathologica, vol. 128, no. 3, pp. 457-459, 2014.
40. K. Stamer, R. Vogel, E. Thies, E. Mandelkow, and E.-M. Mandelkow, "Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress, " Journal of Cell Biology, vol. 156, no. 6, pp. 1051-1063, 2002.
41. A. Kuhla, S. C. Ludwig, B. Kuhla, G. Münch, and B. Vollmar, "Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer's disease brain, " Neurobiology of Aging, vol. 36, no. 2, pp. 753-761, 2015.
42. D. A. Butterfield, A. M. Swomley, and R. Sultana, "Amyloid peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression, " Antioxidants and Redox Signaling, vol. 19, no. 8, pp. 823-835, 2013.
43. M. Barbagallo, F. Marotta, and L. J. Dominguez, "Oxidative stress in patients with Alzheimer's disease: effect of extracts of fermented papaya powder, " Mediators of Inflammation, vol. 2015, Article ID 624801, 6 pages, 2015.
44. K. Aquilano, S. Baldelli, and M. R. Ciriolo, "Glutathione: new roles in redox signalling for an old antioxidant, " Frontiers in Pharmacology, vol. 5, p. 196, 2014.
45. B. Uttara, A. V. Singh, P. Zamboni, and R. T. Mahajan, "Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options, " Current Neuropharmacology, vol. 7, no. 1, pp. 65-74, 2009.
46. L. T. McGrath, B. M. McGleenon, S. Brennan, D. McColl, S. McILroy, and A. P. Passmore, "Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde, " QJM, vol. 94, no. 9, pp. 485-490, 2001.
47. P. Gamba, G. Testa, S. Gargiulo, E. Staurenghi, G. Poli, and G. Leonarduzzi, "Oxidized cholesterol as the driving force behind the development of Alzheimer's disease, " Frontiers in Aging Neuroscience, vol. 7, article 119, 2015.
48. K. Talbot, H.-Y. Wang, H. Kazi et al., "Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline, "The Journal of Clinical Investigation, vol. 122, no. 4, pp. 1316-1338, 2012.
49. H. L. Elfrink, R. Zwart, M. L. Cavanillas, A. J. Schindler, F. Baas, and W. Scheper, "Rab6 is a modulator of the unfolded protein response: implications for Alzheimer's disease, " Journal of Alzheimer's Disease, vol. 28, no. 4, pp. 917-929, 2012.
50. P. I. Moreira, L. M. Sayre, X. Zhu, A. Nunomura, M. A. Smith, and G. Perry, "Detection and localization of markers of oxidative stress by in situ methods: Application in the study of Alzheimer disease, " Methods in Molecular Biology, vol. 610, pp. 419-434, 2010.
51. M. A. Lovell, J. D. Robertson, W. J. Teesdale, J. L. Campbell, and W. R. Markesbery, "Copper, iron and zinc in Alzheimer's disease senile plaques, " Journal of the Neurological Sciences, vol. 158, no. 1, pp. 47-52, 1998.
52. J. A. Molina, F. J. Jiménez-Jiménez, M. V. Aguilar et al., "Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease, " Journal of Neural Transmission, vol. 105, no. 4-5, pp. 479-488, 1998.
53. F. Hane and Z. Leonenko, "Effect of metals on kinetic pathways of amyloid-aggregation, " Biomolecules, vol. 4, no. 1, pp. 101-116, 2014.
54. G. Torsdottir, J. Kristinsson, J. Snaedal, and T. Jóhannesson, "Ceruloplasmin and iron proteins in the serum of patients with Alzheimer's disease, " Dementia and Geriatric Cognitive Disorders Extra, vol. 1, no. 1, pp. 366-371, 2011.
55. P. J. Crouch, A. R. White, and A. I. Bush, "The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease, " FEBS Journal, vol. 274, no. 15, pp. 3775-3783, 2007.
56. M. Schrag, C. Mueller, U. Oyoyo, M. A. Smith, and W. M. Kirsch, "Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion, " Progress inNeurobiology, vol. 94, no. 3, pp. 296-306, 2011.
57. H. Reichmann, "Clinical criteria for the diagnosis of Parkinson's disease, " Neurodegenerative Diseases, vol. 7, no. 5, pp. 284-290, 2010.
58. S. Amor, L. A. N. Peferoen, D. Y. S. Vogel et al., "Inflammation in neurodegenerative diseases-an update, " Immunology, vol. 142, no. 2, pp. 151-166, 2014.
59. S. Engelender, "Ubiquitination of synuclein and autophagy in Parkinson's disease, " Autophagy, vol. 4, no. 3, pp. 372-374, 2008.
60. D. A. Bosco, D. M. Fowler, Q. Zhang et al., "Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate synuclein fibrilization, " Nature Chemical Biology, vol. 2, no. 5, pp. 249-253, 2006.
61. Y. Nakabeppu, D. Tsuchimoto, H. Yamaguchi, and K. Sakumi, "Oxidative damage in nucleic acids and Parkinson's disease, " Journal of Neuroscience Research, vol. 85, no. 5, pp. 919-934, 2007.
62. G. D. Zeevalk, R. Razmpour, and L. P. Bernard, "Glutathione and Parkinson's disease: is this the elephant in the room?" Biomedicine and Pharmacotherapy, vol. 62, no. 4, pp. 236-249, 2008.
63. E. Emmanouilidou, L. Stefanis, and K. Vekrellis, "Cell-produced synuclein oligomers are targeted to, and impair, the 26S proteasome, " Neurobiology of Aging, vol. 31, no. 6, pp. 953-968, 2010.
64. F. Coppedè and L. Migliore, "DNA damage in neurodegenerative diseases, " Mutation Research, vol. 776, pp. 84-97, 2015.
65. R. J. Castellani, G. Perry, S. L. Siedlak et al., "Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans, " Neuroscience Letters, vol. 319, no. 1, pp. 25-28, 2002.
66. K. E. McElhanon, C. Bose, R. Sharma, L. Wu, Y. C. Awasthi, and S. P. Singh, "4 null mouse embryonic fibroblasts exhibit enhanced sensitivity to oxidants: role of 4-hydroxynonenal in oxidant toxicity, " Open Journal of Apoptosis, vol. 02, no. 01, pp. 1-11, 2013.
67. S. J. Lee, K. W. Seo, M. R. Yun et al., "4-Hydroxynonenal enhances MMP-2 production in vascular smooth muscle cells via mitochondrial ROS-mediated activation of the Akt/NF-B signaling pathways, " Free Radical Biology and Medicine, vol. 45, no. 10, pp. 1487-1492, 2008.
68. Z. F. Peng, C. H. V. Koh, Q. T. Li et al., "Deciphering the mechanism of HNE-induced apoptosis in culturedmurine cortical neurons: Transcriptional responses and cellular pathways, " Neuropharmacology, vol. 53, no. 5, pp. 687-698, 2007.
69. A. Ayala, M. F. Muñoz, and S. Argüelles, "Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal, " Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 360438, 31 pages, 2014.
70. S. Camandola, G. Poli, and M. P. Mattson, "The lipid peroxidation product 4-hydroxy-2, 3-nonenal inhibits constitutive and inducible activity of nuclear factor B in neurons, " Molecular Brain Research, vol. 85, no. 1-2, pp. 53-60, 2000.
71. S. Camandola, G. Poli, and M. P. Mattson, "The lipid peroxidation product 4-hydroxy-2, 3-nonenal increases AP-1-binding activity through caspase activation in neurons, " Journal of Neurochemistry, vol. 74, no. 1, pp. 159-168, 2000.
72. Z. Guo, S. Xu, N. Du, J. Liu, Y. Huang, and M. Han, "Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: involvement of the dopamine system, " Neuroscience Letters, vol. 616, pp. 152-159, 2016.
73. O. von Bohlen Und Halbach, A. Schober, R. Hertel, and K. Unsicker, "MPTP treatment impairs tyrosine hydroxylase immunopositive fibers not only in the striatum, but also in the amygdala, " Neurodegenerative Diseases, vol. 2, no. 1, pp. 44-48, 2005.
74. R. Betarbet, T. B. Sherer, G. MacKenzie, M. Garcia-Osuna, A. V. Panov, and J. T. Greenamyre, "Chronic systemic pesticide exposure reproduces features of Parkinson's disease, " Nature Neuroscience, vol. 3, no. 12, pp. 1301-1306, 2000.
75. W. Dauer and S. Przedborski, "Parkinson's disease:mechanisms and models, " Neuron, vol. 39, no. 6, pp. 889-909, 2003.
76. J. Lotharius and K. L. O'Malley, "The Parkinsonism-inducing drug 1-methyl-4-phenylpyridiniumtriggers intracellular dopamine oxidation. A novel mechanism of toxicity, " The Journal of Biological Chemistry, vol. 275, no. 49, pp. 38581-38588, 2000.
77. T. G. Hastings, "The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease, " Journal of Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 469-472, 2009.
78. V. Jackson-Lewis and R. J. Smeyne, "MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview, " Neurotoxicity Research, vol. 7, no. 3, pp. 193-201, 2005.
79. C. Proukakis, C. G. Dudzik, T. Brier et al., "A novel synuclein missensemutation in Parkinson disease, " Neurology, vol. 80, no. 11, pp. 1062-1064, 2013.
80. K. A. Conway, J.-C. Rochet, R. M. Bieganski, and P. T. J. Lansbury, "Kinetic stabilization of the synuclein protofibril by a dopamine-synuclein adduct, " Science, vol. 294, no. 5545, pp. 1346-1349, 2001.
81. J.-C. Rochet, T. F. Outeiro, K. A. Conway et al., "Interactions among synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease, " Journal of Molecular Neuroscience, vol. 23, no. 1-2, pp. 23-33, 2004.
82. V. Swarup and J.-P. Julien, "ALS pathogenesis: recent insights from genetics and mouse models, " Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 2, pp. 363-369, 2011.
83. I. Niebrój-Dobosz, D. Dziewulska, and H. Kwiecínski, "Oxidative damage to proteins in the spinal cord in amyotrophic lateral sclerosis (ALS), " Folia Neuropathologica, vol. 42, no. 3, pp. 151-156, 2004.
84. D. Liu, F. Bao, J. Wen, and J. Liu, "Mutation of superoxide dismutase elevates reactive species: comparison of nitration and oxidation of proteins in different brain regions of transgenic mice with amyotrophic lateral sclerosis, " Neuroscience, vol. 146, no. 1, pp. 255-264, 2007.
85. D. A. Drechsel, A. G. Estévez, L. Barbeito, and J. S. Beckman, "Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS, " Neurotoxicity Research, vol. 22, no. 4, pp. 251-264, 2012.
86. M. Bogdanov, R. H. Brown Jr., W. Matson et al., "Increased oxidative damage to DNA in ALS patients, " Free Radical Biology and Medicine, vol. 29, no. 7, pp. 652-658, 2000.
87. K. Abe, L.-H. Pan, M. Watanabe, H. Konno, T. Kato, and Y. Itoyama, "Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis, " Neurological Research, vol. 19, no. 2, pp. 124-128, 1997.
88. M. R. Cookson, F. M. Menzies, P. Manning et al., "Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress, " Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 3, no. 2, pp. 75-85, 2002.
89. Y. Hayashi, K. Homma, and H. Ichijo, "SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS, " Advances in Biological Regulation, vol. 60, pp. 95-104, 2016.
90. J. Brettschneider, K. Arai, K. Del Tredici et al., "TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord, " Acta Neuropathologica, vol. 128, no. 3, pp. 423-437, 2014.
91. I. R. A. Mackenzie, E. H. Bigio, P. G. Ince et al., "Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations, " Annals of Neurology, vol. 61, no. 5, pp. 427-434, 2007.
92. S. Maekawa, P. N. Leigh, A. King et al., "TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations, " Neuropathology, vol. 29, no. 6, pp. 672-683, 2009.
93. M. J. Winton, L. M. Igaz, M. M. Wong, L. K. Kwong, J. Q. Trojanowski, and V. M.-Y. Lee, "Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation, " The Journal of Biological Chemistry, vol. 283, no. 19, pp. 13302-13309, 2008.
94. R. I. Gregory, K.-P. Yan, G. Amuthan et al., "TheMicroprocessor complex mediates the genesis of microRNAs, " Nature, vol. 432, no. 7014, pp. 235-240, 2004.
95. Z.-S. Xu, "Does a loss of TDP-43 function cause neurodegeneration?" Molecular Neurodegeneration, vol. 7, article 27, 2012.
96. L. Liu-Yesucevitz, A. Bilgutay, Y.-J. Zhang et al., "Tar DNA binding protein-43 (TDP-43) associates with stress granules: Analysis of cultured cells and pathological brain tissue, " PLoS ONE, vol. 5, no. 10, Article IDe13250, 2010.
97. E. Bentmann, M. Neumann, S. Tahirovic, R. Rodde, D. Dormann, and C. Haass, "Requirements for stress granule recruitment of fused in sarcoma (FUS) and TARDNA-binding protein of 43 kDa (TDP-43), "The Journal of Biological Chemistry, vol. 287, no. 27, pp. 23079-23094, 2012.
98. C. Colombrita, E. Zennaro, C. Fallini et al., "TDP-43 is recruited to stress granules in conditions of oxidative insult, " Journal of Neurochemistry, vol. 111, no. 4, pp. 1051-1061, 2009.
99. T. C. Frank-Cannon, L. T. Alto, F. E. McAlpine, and M. G. Tansey, "Does neuroinflammation fan the flame in neurodegenerative diseases?" Molecular Neurodegeneration, vol. 4, article 47, 2009.
100. G. C. Brown, "Mechanisms of inflammatory neurodegeneration: INOS and NADPH oxidase, " Biochemical Society Transactions, vol. 35, no. 5, pp. 1119-1121, 2007.
101. G. Cappellano, M. Carecchio, T. Fleetwood et al., "Immunity and inflammation in neurodegenerative diseases, " American Journal of Neurodegenerative Disease, vol. 2, no. 2, pp. 89-107, 2013.
102. B. A. Citron, J. S. Dennis, R. S. Zeitlin, and V. Echeverria, "Transcription factor Sp1 dysregulation in Alzheimer's disease, " Journal of Neuroscience Research, vol. 86, no. 11, pp. 2499-2504, 2008.
103. Q. Jiang, M. Heneka, and G. E. Landreth, "The role of peroxisome proliferator-activated receptor-(PPAR ) in Alzheimer's disease: Therapeutic implications, " CNS Drugs, vol. 22, no. 1, pp. 1-14, 2008.
104. I. Granic, A. M. Dolga, I. M. Nijholt, G. Van Dijk, and U. L. M. Eisel, "Inflammation and NF-B in Alzheimer's disease and diabetes, " Journal of Alzheimer's Disease, vol. 16, no. 4, pp. 809-821, 2009.
105. T. Town, V. Nikolic, and J. Tan, "The microglial'activation' continuum: from innate to adaptive responses, " Journal of Neuroinflammation, vol. 2, article 24, 2005.
106. G. Halliday, S. R. Robinson, C. Shepherd, and J. Kril, "Alzheimer's disease and inflammation: A reviewof cellular and therapeutic mechanisms, " Clinical and Experimental Pharmacology and Physiology, vol. 27, no. 1-2, pp. 1-8, 2000.
107. G. C. Brown and A. Bal-Price, "Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria, " Molecular Neurobiology, vol. 27, no. 3, pp. 325-355, 2003.
108. R. Strohmeyer, M. Ramirez, G. J. Cole, K. Mueller, and J. Rogers, "Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain, " Journal of Neuroimmunology, vol. 131, no. 1-2, pp. 135-146, 2002.
109. D. Zhang, X. Hu, L. Qian et al., "Microglial MAC1 receptor and PI3K are essential inmediating amyloid peptide-induced microglial activation and subsequent neurotoxicity, " Journal of Neuroinflammation, vol. 8, no. 1, article 3, 2011.
110. F.-S. Shie and R. L. Woltjer, "Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease, " Current Medicinal Chemistry, vol. 14, no. 27, pp. 2865-2871, 2007.
111. K. Bettens, K. Sleegers, and C. Van Broeckhoven, "Genetic insights in Alzheimer's disease, " The Lancet Neurology, vol. 12, no. 1, pp. 92-104, 2013.
112. C. M. Karch, C. Cruchaga, and A. M. Goate, "Alzheimer's disease genetics: fromthe bench to the clinic, " Neuron, vol. 83, no. 1, pp. 11-26, 2014.
113. R. Guerreiro, A. Wojtas, J. Bras et al., "TREM2 variants in Alzheimer's disease, "The New England Journal of Medicine, vol. 368, no. 2, pp. 117-127, 2013.
114. D. Harold, R. Abraham, P. Hollingworth et al., "Genomewide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, " Nature Genetics, vol. 41, no. 10, pp. 1088-1093, 2009.
115. J.-C. Lambert, S. Heath, G. Even et al., "Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease, " Nature Genetics, vol. 41, no. 10, pp. 1094-1099, 2009.
116. M. Reale, N. H. Greig, and M. A. Kamal, "Peripheral chemocytokine profiles in Alzheimer's and Parkinson's diseases, " Mini-Reviews in Medicinal Chemistry, vol. 9, no. 10, pp. 1229-1241, 2009.
117. L. Qian and P. M. Flood, "Microglial cells and Parkinson's disease, " Immunologic Research, vol. 41, no. 3, pp. 155-164, 2008.
118. E. C. Hirsch, T. Breidert, E. Rousselet, S. Hunot, A. Hartmann, and P. P. Michel, "The role of glial reaction and inflammation in Parkinson's disease, " Annals of the New York Academy of Sciences, vol. 991, pp. 214-228, 2003.
119. J. Segura-Aguilar, I. Paris, P. Muñoz, E. Ferrari, L. Zecca, and F. A. Zucca, "Protective and toxic roles of dopamine in Parkinson's disease, " Journal of Neurochemistry, vol. 129, no. 6, pp. 898-915, 2014.
120. P. K. Mander, A. Jekabsone, and G. C. Brown, "Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase, " The Journal of Immunology, vol. 176, no. 2, pp. 1046-1052, 2006.
121. R. Dringen, "Oxidative and antioxidative potential of brain microglial cells, " Antioxidants and Redox Signaling, vol. 7, no. 9-10, pp. 1223-1233, 2005.
122. N. Shibata, A. Kakita, H. Takahashi et al., "Activation of signal transducer and activator of transcription-3 in the spinal cord of sporadic amyotrophic lateral sclerosis patients, " Neurodegenerative Diseases, vol. 6, no. 3, pp. 118-126, 2009.
123. R. Zhang, K. G. Hadlock, H. Do et al., "Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS), " Journal of Neuroimmunology, vol. 230, no. 1-2, pp. 114-123, 2011.
124. J. Kuhle, R. L. P. Lindberg, A. Regeniter et al., "Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis, " European Journal of Neurology, vol. 16, no. 6, pp. 771-774, 2009.
125. M. Fiala, M. Chattopadhay, A. La Cava et al., "IL-17A is increased in the serumand in spinal cord CD8 and mast cells of ALS patients, " Journal of Neuroinflammation, vol. 7, article 76, 2010.
126. M. Rentzos, A. Rombos, C. Nikolaou et al., "Interleukin-15 and Interleukin-12 are elevated in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis, " European Neurology, vol. 63, no. 5, pp. 285-290, 2010.
127. I. L. Goldknopf, E. A. Sheta, J. Bryson et al., "Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease, " Biochemical and Biophysical Research Communications, vol. 342, no. 4, pp. 1034-1039, 2006.
128. G. De Chiara, M. E. Marcocci, R. Sgarbanti et al., "Infectious agents and neurodegeneration, " Molecular Neurobiology, vol. 46, no. 3, pp. 614-638, 2012.
129. D. B. McGavern and S. S. Kang, "Illuminating viral infections in the nervous system, " Nature Reviews Immunology, vol. 11, no. 5, pp. 318-329, 2011.
130. K. Kristensson, "Microbes' roadmap to neurons, " Nature Reviews Neuroscience, vol. 12, no. 6, pp. 345-357, 2011.
131. S. Toovey, S. S. Jick, and C. R. Meier, "Parkinson's disease or Parkinson symptoms following seasonal influenza, " Influenza and Other Respiratory Viruses, vol. 5, no. 5, pp. 328-333, 2011.
132. R. T. Ravenholt and W. Foege, "1918 influenza, encephalitis lethargica, parkinsonism, " The Lancet, vol. 320, no. 8303, pp. 860-864, 1982.
133. J. S. Oxford, "Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology, " Reviews in Medical Virology, vol. 10, no. 2, pp. 119-133, 2000.
134. T. T. Rohn and L. W. Catlin, "Immunolocalization of influenza A virus and markers of inflammation in the human Parkinson's disease brain, " PLoS ONE, vol. 6, no. 5, Article ID e20495, 2011.
135. J. P. Anderson, D. E. Walker, J. M. Goldstein et al., "Phosphorylation of Ser-129 is the dominant pathological modification of synuclein in familial and sporadic lewy body disease, " The Journal of Biological Chemistry, vol. 281, no. 40, pp. 29739-29752, 2006.
136. H. Jang, D. Boltz, K. Sturm-Ramirez et al., "Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 14063-14068, 2009.
137. R. J. Whitley, "Herpesviruses, " in Medical Microbiology, S. Baron, Ed., University of Texas Medical Branch at Galveston, Galveston, Tex, USA, 1996.
138. M. J. Ball, "Limbic predilection in Alzheimer dementia: is reactivated herpesvirus involved?" Canadian Journal ofNeurological Sciences, vol. 9, no. 3, pp. 303-306, 1982.
139. A. Gannicliffe, R. N. Sutton, and R. F. Itzhaki, "Viruses, brain and immunosuppression, " PsychologicalMedicine, vol. 16, no. 2, pp. 247-249, 1986.
140. M. A. Wozniak, S. J. Shipley, M. Combrinck, G. K. Wilcock, and R. F. Itzhaki, "Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients, " Journal of Medical Virology, vol. 75, no. 2, pp. 300-306, 2005.
141. R. F. Itzhaki and M. A. Wozniak, "Herpes simplex virus type 1 in Alzheimer's disease: The enemywithin, " Journal of Alzheimer's Disease, vol. 13, no. 4, pp. 393-405, 2008.
142. M. A. Wozniak, A. P. Mee, and R. F. Itzhaki, "Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques, " The Journal of Pathology, vol. 217, no. 1, pp. 131-138, 2009.
143. I. Mori, Y. Kimura, H. Naiki et al., "Reactivation of HSV-1 in the brain of patients with familial Alzheimer's disease, " Journal of Medical Virology, vol. 73, no. 4, pp. 605-611, 2004.
144. L. Letenneur, K. Pérès, H. Fleury et al., "Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: A population-based cohort study, " PLoSONE, vol. 3, no. 11, Article ID e3637, 2008.
145. S. Santana, M. Recuero, M. J. Bullido, F. Valdivieso, and J. Aldudo, "Herpes simplex virus type I induces the accumulation of intracellular amyloid in autophagic compartments and the inhibition of the non-amyloidogenic pathway in human neuroblastoma cells, " Neurobiology of Aging, vol. 33, no. 2, pp. 430. e19-430. e33, 2012.
146. R. Piacentini, L. Civitelli, C. Ripoli et al., "HSV-1 promotes Ca2+-mediated APP phosphorylation and A accumulation in rat cortical neurons, " Neurobiology of Aging, vol. 32, no. 12, pp. 2323. e13-2323. e26, 2011.
147. G. De Chiara, M. E. Marcocci, L. Civitelli et al., "APP processing induced by herpes simplex virus type 1 (HSV-1) yields several APP fragments in human and rat neuronal cells, " PLoS ONE, vol. 5, no. 11, Article ID e13989, 2010.
148. R. Lerchundi, R. Neira, S. Valdivia et al., "Tau cleavage at D421 by caspase-3 is induced in neurons and astrocytes infected with Herpes Simplex Virus Type 1, " Journal of Alzheimer's Disease, vol. 23, no. 3, pp. 513-520, 2011.
149. E. Porcellini, I. Carbone, M. Ianni, and F. Licastro, "Alzheimer's disease gene signature says: beware of brain viral infections, " Immunity and Ageing, vol. 7, article 16, 2010.
150. M. E. Westarp, P. Ferrante, H. Perron, P. Bartmann, and H. H. Kornhuber, "Sporadic ALS/MND: A global neurodegeneration with retroviral involvement?" Journal of the Neurological Sciences, vol. 129, supplement, pp. 145-147, 1995.
151. P. Ferrante, M. E. Westarp, R. Mancuso et al., "HTLV tax-rex DNA and antibodies in idiopathic amyotrophic lateral sclerosis, " Journal of the Neurological Sciences, vol. 129, supplement, pp. 140-144, 1995.
152. M. T. T. Silva, A. C. C. Leite, A. H. Alamy, L. Chimelli, M. J. Andrada-Serpa, and A. Q. C. Araújo, "ALS syndrome in HTLVI infection, " Neurology, vol. 65, no. 8, pp. 1332-1333, 2005.
153. J. F. Zachary, T. V. Baszler, R. A. French, and K. W. Kelley, "MouseMoloney leukemia virus infects microglia but not neurons even though it induces motor neuron disease, " Molecular Psychiatry, vol. 2, no. 2, pp. 104-106, 1997.
154. A. J. Steele, A. Al-Chalabi, K. Ferrante, M. E. Cudkowicz, R. H. Brown Jr., and J. A. Garson, "Detection of serum reverse transcriptase activity in patients withALS and unaffected blood relatives, " Neurology, vol. 64, no. 3, pp. 454-458, 2005.
155. S. Mizutani, D. Boettiger, and H. M. Temin, "A DNA-depenent DNA polymerase and a DNA endonuclease in virions of Rous sarcoma virus, " Nature, vol. 228, no. 5270, pp. 424-427, 1970.
156. M. V. Viola, M. Frazier, L. White, J. Brody, and S. Spiegelman, "RNA instructed DNA polymerase activity in a cytoplasmic particulate fraction in brains from Guamanian patients, " Journal of Experimental Medicine, vol. 142, no. 2, pp. 483-494, 1975.
157. D. J. L. MacGowan, S. N. Scelsa, T. E. Imperato, K.-N. Liu, P. Baron, and B. Polsky, "A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS, " Neurology, vol. 68, no. 22, pp. 1944-1946, 2007.
158. A. L. McCormick, R. H. Brown Jr., M. E. Cudkowicz, A. Al-Chalabi, and J. A. Garson, "Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate, " Neurology, vol. 70, no. 4, pp. 278-283, 2008.
159. T. Alfahad and A. Nath, "Retroviruses and amyotrophic lateral sclerosis, " Antiviral Research, vol. 99, no. 2, pp. 180-187, 2013.
160. S. O. A. Oluwole, Y. Yao, S. Conradi, K. Kristensson, and H. Karlsson, "Elevated levels of transcripts encoding a human retroviral envelope protein (syncytin) in muscles from patients with motor neuron disease, " Amyotrophic Lateral Sclerosis, vol. 8, no. 2, pp. 67-72, 2007.
161. W. Li, M.-H. Lee, L. Henderson et al., "Human endogenous retrovirus-K contributes to motor neuron disease, " Science Translational Medicine, vol. 7, no. 307, p. 307ra153, 2015.
162. M. R. Ciriolo, A. T. Palamara, S. Incerpi et al., "Loss of GSH, oxidative stress, and decrease of intracellular pH as sequential steps in viral infection, "The Journal of Biological Chemistry, vol. 272, no. 5, pp. 2700-2708, 1997.
163. G. Gong, G. Waris, R. Tanveer, and A. Siddiqui, "Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-B, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 17, pp. 9599-9604, 2001.
164. P. Kaul, M. C. Biagioli, I. Singh, and R. B. Turner, "Rhinovirusinduced oxidative stress and interleukin-8 elaboration involves p47-phox but is independent of attachment to intercellular adhesion molecule-1 and viral replication, " Journal of Infectious Diseases, vol. 181, no. 6, pp. 1885-1890, 2000.
165. L. Nencioni, A. Iuvara, K. Aquilano et al., "Influenza A virus replication is dependent on an antioxidant pathway that involves GSH and Bcl-2, " The FASEB Journal, vol. 17, no. 6, pp. 758-760, 2003.
166. E. Peterhans, "Oxidants and antioxidants in viral diseases: disease mechanisms and metabolic regulation, " Journal of Nutrition, vol. 127, supplement 5, pp. 962S-965S, 1997.
167. L. W. Enquist, P. J. Husak, B. W. Banfield, and G. A. Smith, "Infection and spread of alphaherpesviruses in the nervous system, " Advances in Virus Research, vol. 51, pp. 237-347, 1998.
168. S. Wickham, B. Lu, J. Ash, and D. J. J. Carr, "Chemokine receptor deficiency is associated with increased chemokine expression in the peripheral and central nervous systems and increased resistance to herpetic encephalitis, " Journal of Neuroimmunology, vol. 162, no. 1-2, pp. 51-59, 2005.
169. C. Nucci, A. T. Palamara, M. R. Ciriolo et al., "Imbalance in corneal redox state during herpes simplex virus 1-induced keratitis in rabbits. Effectiveness of exogenous glutathione supply, " Experimental Eye Research, vol. 70, no. 2, pp. 215-220, 2000.
170. A. T. Palamara, C.-F. Perno, M. R. Ciriolo et al., "Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication, " Antiviral Research, vol. 27, no. 3, pp. 237-253, 1995.
171. T. Valyi-Nagy and T. S. Dermody, "Role of oxidative damage in the pathogenesis of viral infections of the nervous system, " Histology and Histopathology, vol. 20, no. 3, pp. 957-967, 2005.
172. S. J. Schachtele, S. Hu, M. R. Little, and J. R. Lokensgard, "Herpes simplex virus induces neural oxidative damage via microglial cell Toll-like receptor-2, " Journal of Neuroinflammation, vol. 7, article 35, 2010.
173. J. Kavouras, E. Prandovszky, K. Valyi-Nagy et al., "Herpes simplex virus type 1 infection induces oxidative stress and the release of bioactive lipid peroxidation by-products in mouse P19N neural cell cultures, " Journal of NeuroVirology, vol. 13, no. 5, pp. 416-425, 2007.
174. S. Fujii, T. Akaike, and H. Maeda, "Role of nitric oxide in pathogenesis of herpes simplex virus encephalitis in rats, " Virology, vol. 256, no. 2, pp. 203-212, 1999.
175. S. Santana, I. Sastre, M. Recuero, M. J. Bullido, and J. Aldudo, "Oxidative stress enhances neurodegenerationmarkers induced by herpes simplex virus type 1 infection in human neuroblastoma cells, " PLoS ONE, vol. 8, no. 10, Article IDe75842, 2013.
176. R. Sgarbanti, L. Nencioni, D. Amatore et al., "Redox regulation of the influenza hemagglutinin maturation process: A new cellmediated strategy for anti-influenza therapy, " Antioxidants and Redox Signaling, vol. 15, no. 3, pp. 593-606, 2011.
177. L. Nencioni, G. De Chiara, R. Sgarbanti et al., "Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication, " The Journal of Biological Chemistry, vol. 284, no. 23, pp. 16004-16015, 2009.
178. E. Garaci, A. T. Palamara, M. R. Ciriolo et al., "Intracellular GSH content and HIV replication in humanmacrophages, " Journal of Leukocyte Biology, vol. 62, no. 1, pp. 54-59, 1997.
179. P. V. B. Reddy, N. Gandhi, T. Samikkannu et al., "HIV-1 gp120 induces antioxidant response element-mediated expression in primary astrocytes: role in HIV associated neurocognitive disorder, " Neurochemistry International, vol. 61, no. 5, pp. 807-814, 2012.
180. K. Dasuri, L. Zhang, and J. N. Keller, "Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis, " Free Radical Biology and Medicine, vol. 62, pp. 170-185, 2013.